Table 3.

Mutational Rates of Genes in All Patients

Gene	No. of Patients (PMF/PV/ET)	No. of Patients Tested	No. (%) of Patients Mutated
JAK2	72/33/27	132	87 (65.91)
CALR	17/0/2	19	6 (31.58)
ASXL1	45/32/27	104	22 (21.15)
TET2	44/32/27	103	20 (19.42)
SRSF2	43/32/27	102	8 (7.84)
MPL	52/32/27	111	8 (7.21)
SF3B1	43/32/27	102	7 (6.86)
DNMT3A	44/32/27	103	7 (6.80)
KMT2A	29/22/14	65	4 (6.15)
CBL	43/32/27	102	6 (5.88)
IDH2	44/32/27	103	5 (4.85)
FLT3	30/22/14	66	3 (4.55)
U2AF1	43/32/27	102	4 (3.92)
EZH2	44/32/27	103	4 (3.88)
CUX1	29/22/14	65	2 (3.08)
ETV6	44/32/27	103	3 (2.91)
PHF6	44/32/27	103	3 (2.91)
IDH1	44/32/27	103	2 (1.94)
TP53	44/32/27	103	2 (1.94)
CSF3R	29/22/14	65	1 (1.54)
KRAS	29/22/14	65	1 (1.54)
SH2B3	29/22/14	65	1 (1.54)
NRAS	43/32/27	102	1 (0.98)
ZRSR2	43/32/27	102	1 (0.98)
KIT	44/32/27	103	1 (0.97)
ABL1	29/22/14	65	0 (0.00)
CEBPA	29/22/14	65	0 (0.00)
MYD88	29/22/14	65	0 (0.00)
NPM1	44/32/27	103	0 (0.00)
RUNX1	44/32/27	103	0 (0.00)
SETBP1	43/32/27	102	0 (0.00)
WT1	29/22/14	65	0 (0.00)

ET, essential thrombocytosis; PMF, primary myelofibrosis; PV, polycythemia vera.